FDA’s Woodcock Prioritizes Trial Networks As Drug Development Solution
This article was originally published in The Tan Sheet
Executive Summary
Culture change, not congressional action, is needed to change clinical trials system and move toward faster drug development, FDA’s drug center director tells the Energy & Commerce Committee.